IVD Firms Can Expect Longer Quality System Inspections - ORA Staffer
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of in vitro diagnostic products under the jurisdiction of FDA's Center for Biologics Evaluation and Research can expect longer and more comprehensive quality system inspections under the center's recently launched "Team Biologics" initiative.